SK281249B6 - (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom - Google Patents

(-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom Download PDF

Info

Publication number
SK281249B6
SK281249B6 SK1257-93A SK125793A SK281249B6 SK 281249 B6 SK281249 B6 SK 281249B6 SK 125793 A SK125793 A SK 125793A SK 281249 B6 SK281249 B6 SK 281249B6
Authority
SK
Slovakia
Prior art keywords
crystalline form
oxathiolan
cis
amino
hydroxymethyl
Prior art date
Application number
SK1257-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK125793A3 (en
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK281249(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK125793A3 publication Critical patent/SK125793A3/sk
Publication of SK281249B6 publication Critical patent/SK281249B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
SK1257-93A 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom SK281249B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds
PCT/EP1992/001213 WO1992021676A1 (fr) 1991-06-03 1992-06-02 Derives d'oxathiolane cristallins

Publications (2)

Publication Number Publication Date
SK125793A3 SK125793A3 (en) 1994-11-09
SK281249B6 true SK281249B6 (sk) 2001-01-18

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1257-93A SK281249B6 (sk) 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom

Country Status (31)

Country Link
US (1) US5905082A (fr)
EP (2) EP1099700A1 (fr)
JP (1) JP2851480B2 (fr)
KR (1) KR100244008B1 (fr)
AP (1) AP300A (fr)
AT (1) ATE212630T1 (fr)
AU (2) AU656379B2 (fr)
BG (1) BG60914B1 (fr)
CA (2) CA2070230C (fr)
CZ (1) CZ284513B6 (fr)
DE (1) DE69232387T2 (fr)
DK (1) DK0517145T3 (fr)
ES (1) ES2171158T3 (fr)
GB (1) GB9111902D0 (fr)
GE (1) GEP19991834B (fr)
HK (1) HK1009599A1 (fr)
IE (2) IE921780A1 (fr)
IL (1) IL102073A (fr)
IS (2) IS1867B (fr)
MX (1) MX9202619A (fr)
NO (1) NO301713B1 (fr)
NZ (1) NZ242981A (fr)
OA (1) OA09913A (fr)
PT (1) PT517145E (fr)
RU (1) RU2102393C1 (fr)
SG (1) SG52455A1 (fr)
SK (1) SK281249B6 (fr)
TW (1) TW254939B (fr)
UA (1) UA41265C2 (fr)
WO (1) WO1992021676A1 (fr)
ZA (1) ZA924007B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2690137C (fr) * 2001-03-01 2012-11-13 Gilead Sciences, Inc. Formes cristallines polymorphes et autres de ftc cis
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (fr) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Procede de preparation de polymorphes ii cristallins de lamivudine
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
CA2505130C (fr) * 2002-11-08 2009-10-06 Glaxo Group Limited Compositions pharmaceutiques
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ATE415421T1 (de) * 2004-11-10 2008-12-15 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP5184511B2 (ja) * 2006-04-18 2013-04-17 ルピン・リミテッド 新しい結晶形態のラミブジン
AR068374A1 (es) * 2007-09-06 2009-11-11 Combino Pharm Sl Nuevas composiciones farmaceuticas del complejo lamivudina beta - ciclodextrina
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
WO2009069011A1 (fr) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Procédé de préparation de 1,3-oxathiolanes substitués
AU2008331167A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
WO2009069013A1 (fr) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Forme cristalline i de lamivudine et sa préparation
WO2009127996A1 (fr) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Nouvelle forme cristalline de lamivudine
EP2318398A4 (fr) * 2008-09-01 2011-12-07 Hetero Research Foundation Procédé de préparation d'une forme polymorphe de lamivudine
EP2350065A1 (fr) * 2008-11-12 2011-08-03 Lupin Ltd. Nouveau polymorphe de l'emtricitabine et procédé pour sa préparation
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
EP2435052B1 (fr) * 2009-05-27 2015-07-15 Hetero Research Foundation Formes pharmaceutiques solides de lamivudine s'administrant par voie orale avec isomalt
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz
WO2011045815A2 (fr) 2009-10-14 2011-04-21 Matrix Laboratories Ltd. Procédé pour la préparation de lamivudine et nouveaux sels dans sa fabrication
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
CA2789078A1 (fr) * 2010-02-12 2011-08-18 Merck Sharp & Dohme Corp. Preparation de la forme i de la lamivudine
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
WO2013021290A1 (fr) 2011-08-05 2013-02-14 Lupin Limited Procédé stéréosélectif de préparation de nucléosides 1,3-oxathiolane
WO2013168066A1 (fr) 2012-05-05 2013-11-14 Lupin Limited Procédé amélioré de fabrication de lamivudine de forme i
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides

Also Published As

Publication number Publication date
GB9111902D0 (en) 1991-07-24
US5905082A (en) 1999-05-18
DK0517145T3 (da) 2002-05-06
SG52455A1 (en) 1998-09-28
EP1099700A1 (fr) 2001-05-16
SK125793A3 (en) 1994-11-09
NO301713B1 (no) 1997-12-01
DE69232387T2 (de) 2002-09-26
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
PT517145E (pt) 2002-07-31
MX9202619A (es) 1992-12-01
DE69232387D1 (de) 2002-03-14
NO922182D0 (no) 1992-06-02
AU656379B2 (en) 1995-02-02
JPH06211848A (ja) 1994-08-02
BG60914B1 (bg) 1996-06-28
OA09913A (en) 1994-09-15
BG98254A (bg) 1994-07-29
RU2102393C1 (ru) 1998-01-20
ZA924007B (en) 1993-04-28
AU1881092A (en) 1993-01-08
CA2070230A1 (fr) 1992-12-04
IE20020782A1 (en) 2003-04-02
CZ284513B6 (cs) 1998-12-16
AU1736192A (en) 1993-03-11
GEP19991834B (en) 1999-11-05
IE921780A1 (en) 1992-12-16
CA2311988A1 (fr) 1992-12-04
CA2311988C (fr) 2005-11-15
KR100244008B1 (ko) 2000-03-02
AP300A (en) 1994-01-20
EP0517145A1 (fr) 1992-12-09
JP2851480B2 (ja) 1999-01-27
CZ261293A3 (en) 1994-04-13
IL102073A0 (en) 1993-01-14
IL102073A (en) 1996-05-14
ES2171158T3 (es) 2002-09-01
IS3873A (is) 1992-12-04
NO922182L (no) 1992-12-04
IS1867B (is) 2003-05-02
IS4268A (is) 1995-02-27
EP0517145B1 (fr) 2002-01-30
TW254939B (fr) 1995-08-21
HK1009599A1 (en) 1999-06-04
NZ242981A (en) 1994-04-27
CA2070230C (fr) 2004-08-03
WO1992021676A1 (fr) 1992-12-10
KR930000511A (ko) 1993-01-15
UA41265C2 (uk) 2001-09-17

Similar Documents

Publication Publication Date Title
SK281249B6 (sk) (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom
IE83503B1 (en) Crystalline oxathiolane derivatives
SK391091A3 (en) Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
BG60679B1 (bg) Аналози на 1,3-оксатиоланнуклеозида
US20080287378A1 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
EP1727798A1 (fr) Nouvelles 5-acylindolinones contenant aryle, leur production et leur utilisation en tant que medicament
CN107540710B (zh) 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
AU2008331168A1 (en) Crystalline form I of lamivudine and its preparation
KR100453301B1 (ko) 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체
WO2022009863A1 (fr) Dérivé de benzisoxazole
Bambury et al. Mesoionic pyridazine ribonucleosides. A novel biologically active nucleoside metabolite
RU2252211C2 (ru) Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
CN113527395B (zh) 一种腺苷的晶型及其制备方法
EP0456514B1 (fr) 2-Fluoronéplanocine et sa préparation
CZ2015824A3 (cs) Krystalická forma Canagliflozinu a způsob její přípravy
JP2006232671A (ja) 新規セレナゾリン誘導体
CN117466908A (zh) 腺苷受体抑制剂的晶体形式及其制备方法和用途
CN112851640A (zh) 嘧啶苯甲酰胺化合物的硫酸盐及其用途
JPS62270527A (ja) ４１８１−２物質及びその誘導体を有効成分とする抗腫瘍剤
JP2001218595A (ja) 光学活性シクロヘキセン誘導体の製造法およびその合成中間体

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20120602